Paulo Futre
European Champion | Ballon d’Or Silver Medalist | UEFA & La Liga Ambassador | High-Performance Strategy Consultant
2024 Nobel Laureate in Chemistry | Director, UW Institute for Protein Design | Pioneer of Computational Protein Design & AI-Driven Biology
Few scientists have reshaped their field as fundamentally as David Baker, the 2024 Nobel Laureate in Chemistry who invented the ability to design proteins from scratch. Director of the UW Institute for Protein Design and co-founder of 21 biotech companies, Baker reveals how AI and biology are converging to solve humanity's greatest challenges in medicine and sustainability.
Want to book David Baker as a speaker for your event? Please provide the info below and we’ll get in touch within 24h:
David Baker is the 2024 Nobel Laureate in Chemistry and one of the most transformative scientists working at the intersection of biology, artificial intelligence, and medicine. As professor of biochemistry and director of the Institute for Protein Design at the University of Washington, Baker has spent three decades solving what was once considered one of science’s hardest problems: how to design entirely new proteins — molecules that do not exist in nature — from scratch.
Nobel Prize speaker David Baker is best known for developing Rosetta, a computational software suite that cracked the code of protein structure prediction and design. In 2003, his team achieved a landmark breakthrough — designing Top7, the first artificial protein with a completely novel fold. This opened a new frontier in synthetic biology, enabling the creation of proteins that can function as targeted drugs, next-generation vaccines, biosensors, and environmental remediation tools. Baker has since published more than 650 peer-reviewed papers, secured over 100 patents, and co-founded 21 biotechnology companies, several of which have been acquired by major pharmaceutical players including AstraZeneca and Eli Lilly.
His entrepreneurial output has reshaped the biotech landscape of Seattle and beyond. Spinout companies from his lab — including Sana Biotechnology, Lyell Immunotherapeutics, and Xaira Therapeutics — collectively represent hundreds of millions in investment and some of the most promising therapeutic pipelines in oncology, immunology, and gene therapy. More than 100 of his trainees have gone on to independent faculty positions worldwide.
In 2024, Baker was awarded half of the Nobel Prize in Chemistry for his foundational work in computational protein design, sharing the prize with Demis Hassabis and John Jumper of Google DeepMind. The Royal Swedish Academy of Sciences recognized how his methods — now supercharged by AI tools like RoseTTAFold, developed in his lab — are enabling a new generation of molecules with functions never before seen. The Institute for Protein Design has been backed by the Bill & Melinda Gates Foundation, NIH, and the TED Audacious Project, and is widely regarded as the Bell Labs of protein science.
As a speaker, David Baker brings to life one of the most consequential scientific revolutions of our time. His talks translate cutting-edge protein design and AI-driven biology into a vision that resonates powerfully with executive, scientific, and policy audiences alike — illustrating how engineered proteins will reshape medicine, sustainability, and what it means to harness living systems. Audiences leave with a profound understanding of why this moment in biotech is unlike any before it, and what it means for the future of health, industry, and human potential.
For billions of years, evolution has been the sole architect of proteins — the molecules that make life possible. Baker's talk explores how his team broke that monopoly, developing computational tools that can now design entirely new proteins with functions never before seen in nature. Audiences gain a vivid understanding of why this is a pivotal technological moment, comparable to the discovery of electricity or the invention of the transistor, and what it means for drug development, vaccine design, and the future of biotechnology.
Artificial intelligence has already transformed how we find information and generate content. Its next frontier is life itself. Baker explores how AI-driven approaches — from RoseTTAFold to generative protein design — are radically accelerating the pace at which scientists can engineer molecules to address disease, climate change, and industrial challenges. This talk is particularly compelling for technology, healthcare, and investment audiences seeking a grounded view of where AI's most consequential impact will unfold.
With 21 biotechnology companies co-founded and more than 100 trainees leading labs worldwide, Baker is as much a builder as he is a scientist. This session draws on his experience creating Rosetta Commons — a global open-source community — and spinning out companies acquired by AstraZeneca and Eli Lilly. He shares lessons on how open collaboration, not secrecy, can accelerate both scientific progress and commercial success, offering a counterintuitive model for innovation that resonates with leaders across industries.
Newly designed proteins are already showing promise as cancer therapies, universal flu vaccines, plastic-degrading enzymes, and biosensors for environmental monitoring. Baker takes audiences through five grand challenges — in health, sustainability, and technology — that protein design is uniquely positioned to address. The session offers a forward-looking framework for understanding how engineered biology will become a core platform for solving systemic global problems, and why the window to engage with this transformation is now.
| Basic Data Protection Information | |
|---|---|
| Data controller | AURUM SPEAKERS BUREAU S.L. |
| Address | Parc Audiovisual de Catalunya 1, Oficina S11, 08225 Terrassa, Spain |
| Purposes | We will use your data to respond to your requests and deliver our services to you. |
| Marketing | We will only send you marketing correspondence if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Lawful basis | We will only process your data if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Recipients | Generally, only our members of staff who have been duly authorised may access the data that you have provided. |
| Your Rights | You have the right to know what information we hold about you, to rectify it and to erase it, as explained in the additional information available on our website. |
| Additional Information | For more information, please see “PRIVACY POLICY” on our website. |